Nivolumab + Autologous CD30.CAR-T + Fludarabine + Bendamustine
Phase 1Active 0 watching 0 views this week💤 Quiet
32
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Classical Hodgkin Lymphoma
Conditions
Classical Hodgkin Lymphoma, Hodgkin Disease Refractory, Hodgkin Disease Recurrent
Trial Timeline
Jul 25, 2022 → Dec 15, 2037
NCT ID
NCT05352828About Nivolumab + Autologous CD30.CAR-T + Fludarabine + Bendamustine
Nivolumab + Autologous CD30.CAR-T + Fludarabine + Bendamustine is a phase 1 stage product being developed by Bristol Myers Squibb for Classical Hodgkin Lymphoma. The current trial status is active. This product is registered under clinical trial identifier NCT05352828. Target conditions include Classical Hodgkin Lymphoma, Hodgkin Disease Refractory, Hodgkin Disease Recurrent.
Hype Score Breakdown
Clinical
10
Activity
5
Company
9
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05352828 | Phase 1 | Active |
Competing Products
11 competing products in Classical Hodgkin Lymphoma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Camrelizumab + Investigator's choice of Chemotherapy | Jiangsu Hengrui Medicine | Phase 3 | 77 |
| Sabestomig (AZD7789) | AstraZeneca | Phase 1 | 33 |
| Pembrolizumab + Doxorubicin + Vinblastine + Dacarbazine + Brentuximab vedotin | Merck | Phase 2 | 52 |
| Pembrolizumab + Doxorubicin + Vinblastine + Dacarbazine + Bleomycin + Etoposide + Cyclophosphamide + Vincristine + Procarbazine + Prednisone | Merck | Phase 2 | 52 |
| Dacarbazine + Doxorubicin Hydrochloride + Pembrolizumab + Vinblastine Sulfate | Merck | Phase 2 | 52 |
| Carboplatin + Etoposide + Ifosfamide + Pembrolizumab | Merck | Phase 2 | 52 |
| Pembrolizumab (+) Berahyaluronidase alfa | Merck | Phase 2 | 52 |
| Panobinostat | Novartis | Phase 2 | 52 |
| PD1 | Innovent Biologics | Phase 2 | 51 |
| Tislelizumab + Salvage Chemotherapy | BeOne Medicines | Phase 3 | 74 |
| GEN3017 | Genmab | Phase 1/2 | 38 |